Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
- Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 18 participantsVery low